Replication FailureOpen accessMedicine· cited by 564

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Eugenia Abaleke; Mustafa Abbas; Sadia Abbasi; Alfie Abbott; Ashraf Omar Abdelaziz; Sherif Abdelbadiee; Mohamed A. O. Abdelfattah; Basir Abdul · 2021 · The Lancet

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

BACKGROUND: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19. METHODS: In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual st

Abstract by Eugenia Abaleke; Mustafa Abbas; Sadia Abbasi; Alfie Abbott; Ashraf Omar Abdelaziz; Sherif Abdelbadiee; Mohamed A. O. Abdelfattah; Basir Abdul, The Lancet (2021) — licensed CC BY 4.0.

Read the full paper (open access)